SCHEMBL2567865

SCHEMBL2567865

CCOC(=O)c1ocnc1CC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TSHR P16473 1/20 0.39
PDE4D Q08499 1/20 0.39
KDM4E B2RXH2 2/20 0.38
AHR P35869 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13545979 0.87 PLK1 (0.43) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL23635692 0.85 CA12 (0.38) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL28816669 0.84 PLK1 (0.39) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL2139059 0.82 ALDH1A1 (0.48) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL29620241 0.81 KDM4E (0.41) CYP1A2CYP2C9CYP2C19TSHRKDM4E
SCHEMBL25368994 0.81 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL21854494 0.80 GLP1R (0.46) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL21854511 0.80 ALDH1A1 (0.42) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL3714376 0.79 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19L3MBTL1TSHR
SCHEMBL2570641 0.78 KMT2A (0.40) TSHRKDM4ENPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1987030-B1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LTD (GB) 2011-11-09 EP disclosed
US-7691877-B2 Pharmaceuticals PFIZER INC. (US) 2010-04-06 US disclosed
EP-1987030-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS Pfizer Limited (GB) 2008-11-05 EP disclosed
WO-2007093901-A1 3 -DEAZAPURINE DERIVATIVES AS TLR7 MODULATORS PFIZER LIMITED (GB) 2007-08-23 WO disclosed
US-20070197478-A1 NOVEL PHARMACEUTICALS PFIZER LIMITED 2007-08-23 US disclosed
US-5324723-A Analgesics MERCK SHARPE & DOHME LTD. 1994-06-28 US disclosed
EP-0307141-B1 OXAZOLES AND THIAZOLES FOR THE TREATMENT OF SENILE DEMENTIA MERCK SHARP & DOHME LTD. (GB) 1993-01-13 EP disclosed
EP-0307141-A2 Oxazoles and thiazoles for the treatment of senile dementia MERCK SHARP & DOHME LTD. (GB) 1989-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197478-A1 NOVEL PHARMACEUTICALS TLR3, HAVCR2, TLR9 CYP1A2 1104/4885CYP2C9 2301/4885CYP2C19 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.